Biotechnology - Clinical-Stage Therapeutics (Rare Disease and Neurodegenerative Focus)
Strategic Profile
The company's primary focus is advancing its pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1). The company is conducting a Phase 2b clinical trial using Trappsol® Cyclo™ intravenously in early Alzheimer's disease. The company also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs.
Cyborg Score Rationale
Cyclo is advancing Phase 3 and Phase 2b trials with orphan drug designations in rare but serious indications. However, as a micro-cap clinical-stage company with limited revenue and ongoing capital raises, execution risk is substantial. Success depends heavily on pivotal trial outcomes.
Top Insights
(December 2023) Completed merger with Applied Molecular Transport Inc., extending cash runway into H2 2024 with approximately $11 million cash on hand
Trappsol® Cyclo™ carries orphan drug designations in US and Europe for NPC1, reducing competition and regulatory pathway complexity
Dual-indication strategy targets NPC1 (rare, fatal genetic disease) and early Alzheimer's disease, providing diversified commercial upside
Company maintains cyclodextrin manufacturing and distribution business segment generating operational revenue to offset R&D costs